• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Diabetes, Metabolic Syndrome and Cardiovascular Disease - Product Image

Diabetes, Metabolic Syndrome and Cardiovascular Disease

  • Published: December 2012
  • Region: Global
  • 219 Pages
  • TriMark Publications

FEATURED COMPANIES

  • Abbott Laboratories
  • DexCom
  • Insulet
  • Merck & Co.
  • ONO Pharmaceutical
  • Siemens
  • MORE

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes.

This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health READ MORE >

1. Overview
1.1 Statement of Report
1.2 About this Report
1.3 Scope of the Report
1.4 Methodology
1.5 Executive Summary

2. Introduction
2.1 Demographics of Diabetes
2.1.1 Worldwide Diabetes
2.1.2 U.S. Diabetes
2.2 Economics of Diabetes

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes
3.1 Pre-Diabetes Syndrome
3.2 Metabolic Syndrome
3.3 Diabetes and Inflammation
3.4 Progression of Diabetes
3.5 Complications and Co-Morbidities in Type 2 Diabetes
3.6 Hypoglycemia and Treatment
3.7 Risk Factors and Diabetes
3.8 Cardiovascular Disease (CVD) Facts

4. Pharmaceutical Industry and the Anti-Diabetes Market
4.1 The Worldwide Pharmaceutical Industry
4.2 Total Diabetes Drug Market Size and Growth
4.2.1 Sales of Anti-Diabetic Drugs Continue to Rise
4.3 Epidemiology/Cost of Treatment
4.4 Diabetic Medications Overview
4.4.1 Recent Trends in Diabetic Drug Usage
4.4.2 Market Influence Factors

5. Non-Insulin Anti-Diabetes Products
5.1 Anti-Diabetic Drug Therapy Overview
5.1.1 Sulfonylureas
5.1.2 Meglitinides
5.1.3 Biguanides
5.1.4 Thiazolidinediones (TZDs)
5.1.5 £\-Glucosidase Inhibitors
5.1.6 Incretin Mimetics/Glucagon-like Peptide (GLP-1) Analog
5.1.7 Amylin Analog
5.1.8 DPP-IV Inhibitors
5.1.9 Other Classes
5.1.10 Combination Therapy
5.2 Drivers and Trends
5.2.1 Market Share of Anti-Diabetic Drugs
5.2.2 Forecasts for Anti-Diabetic Drugs
5.2.3 Sales Forecast for the Global Diabetes Market
5.3 The Future
5.3.1 Practice Patterns
5.3.2 New Products in Pipeline
5.4 Anti-Diabetic Drug Patent Expiry
5.5 Regulatory Issues

6. Insulin
6.1 Insulin Markets
6.1.1 Major Players and Market Share
6.2 Insulin and Analogs
6.2.1 Rapid-Acting Insulin
6.2.2 Intermediate-Acting Insulin
6.2.3 Long-Acting Insulin/Ultra Long-Acting Insulin
6.2.4 Insulin Mixtures
6.3 Insulin Analogs
6.4 Non-Insulins in Development
6.5 Pipeline Insulin
6.6 Non-Invasive Insulin Delivery
6.6.1 Inhaled Insulin
6.6.1.1 Inhaled Insulin Overview
6.6.2 Oral Insulin
6.6.3 Transdermal Insulin
6.6.4 Oral Spray Insulin
6.7 Barriers for Non-Injected Insulin
6.8 Patient Potential for Non-Injected Insulin
6.9 Insulin Delivery Devices
6.9.1 Lancets and Lancing Devices
6.9.2 Insulin Pens
6.9.3 Injections Aids
6.9.3.1 Automatic Injectors
6.9.3.2 Syringe Magnifiers
6.9.3.3 Insulin Infusers
6.9.4 Insulin Jet Injectors
6.9.5 Insulin Pumps
6.9.5.1 External Insulin Pumps
6.9.5.2 Implantable Insulin Pumps
6.9.5.3 Insulin Pump Market Share
6.9.5.4 Drivers of Demand for Pumps
6.10 Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Products
7.1 Projections for the Anti-Diabetes Drug Market
7.2 Artificial Pancreas
7.3 Insulin-Producing Cells
7.3.1 Cell Therapy Companies for Diabetes
7.4 Transplantation Procedures
7.4.1 Pancreatic Transplantation
7.4.1.1 Pancreatic Organ Transplantation
7.4.1.2 Allo-Islet Transplantation
7.4.1.3 Transplantation of Encapsulated Pancreatic Cells
7.4.1.4 Implantation of Genetically Engineered-Cells or Embryonic Stem Cells
7.4.2 Current Status
7.5 Gastric Bypass Surgery to Treat Type 2 Diabetes
7.6 Immune Modulators
7.7 Anti-Obesity Drug Xenical to Prevent or Delay Development of Type 2 Diabetes
7.8 Other Anti-Diabetic Therapy Drug Candidates
7.8.1 Lipid Abnormalities
7.8.2 High Blood Pressure
7.8.3 Anticoagulants
7.9 Drugs Used ¡§Off-Label¡¨
7.9.1 Niacin Derivatives
7.9.2 Benfluorex
7.9.3 D-Chiro-Inositol
7.9.4 Warfarin Sodium
7.10 Pipeline Diabetic Drug Candidates
7.11 Drug Research Overview
7.12 Future Anti-Diabetic Drugs in Late-Stage Development

8. Diagnosing Diabetes Using In Vitro Laboratory Tests
8.1 New Diagnostic Guidelines
8.2 Diabetes Tests
8.2.1 Fasting Plasma Glucose (FPG) Test
8.2.2 Glucose Tolerance Test
8.2.3 Test for Glycosylated Hemoglobin
8.2.4 Fructosamine
8.3 Glucose Monitoring
8.3.1 Overview of Market Segment
8.3.2 Competitive Strategies
8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix
8.3.3.1 First-Generation Monitors
8.3.3.2 Second-Generation Monitors
8.3.3.3 Third-Generation SMBG Technologies
8.3.3.4 Product Overview
8.3.3.4.1 LifeScan
8.3.3.4.2 Roche Diagnostics
8.3.3.4.3 Bayer Diagnostics
8.3.3.4.4 Abbott Diagnostics
8.3.3.4.5 Other Players
8.3.4 What Are the Advantages of Using a Continuous Glucose-Monitoring Device?
8.3.5 Other Monitoring Device Advancements
8.3.6 Future of Non-Invasive Glucose Technology

9. Market Trends, Challenges and Strategic Options
9.1 Overview
9.2 Diabetes Drug Market Trends
9.2.1 Overview
9.2.2 Emergence of Therapeutics with Improved Administration Characteristics
9.2.3 Increasing Prevalence of Obesity
9.3 Diabetes Mellitus Market Challenges
9.3.1 Overview
9.3.2 Diabetic Pain Therapeutics
9.3.3 Market Prospects of Inhalable Drugs and Their Ability to Establish Safety Levels
9.3.4 Changing Consumer Preference Drives Product Development in Invasive Technology Segment
9.3.5 Non-Invasive Technology for Revenue Potential
9.3.6 Developing Countries Emerging as Key Markets for Diabetes Monitoring Devices
9.3.7 Consumer-Driven Marketing Campaigns¡XEssential, though Expensive
9.3.8 Escalating Expenditure for R&D and Marketing Triggers Consolidation
9.3.9 Market Size Predictions
9.3.10 Major Competitors
9.4 Strategic Options
9.4.1 Overview
9.4.2 Combined Self-Testing Glucose Monitor with Insulin Delivery
9.4.3 Diabetes Drugs in Pipeline
9.5 FDA Therapeutic Targets
9.5.1 FDA Targets Cardiotoxicity
9.5.2 Avandia FDA Warning
9.6 Outlook to Anti-Diabetes Drugs
9.7 Outlook for Cardiovascular Drugs

10. Company Profiles
10.1 A. Menarini
10.2 Abbott Laboratories
10.3 Amgen
10.4 AstraZeneca
10.5 Bayer
10.6 BodyMedia
10.7 Cybermedical
10.8 Debiotech
10.9 DexCom
10.10 Echo Therapeutics
10.11 Elixir Pharmaceuticals
10.12 Eksigent
10.13 Flamel Technologies
10.14 GlaxoSmithKline
10.15 GlucoLight
10.16 Insulet
10.17 iSense Corporation
10.18 Isis Pharmaceuticals, Inc.
10.19 Johnson & Johnson
10.20 KYORIN
10.21 M-Biotech
10.22 Medtronic
10.23 Merck & Co.
10.24 Merck KGaA
10.25 MicroIslet
10.26 Mitsubishi Tanabe Pharma Corporation
10.27 Nipro Diabetes Systems
10.28 Novartis
10.29 Novo Nordisk
10.30 Novocell
10.31 ONO Pharmaceutical
10.32 Orexigen Therapeutics
10.33 Pfizer
10.34 ReNeuron
10.35 Roche Diagnostics
10.36 Sanofi-Aventis
10.37 Sensors for Medicine and Science
10.38 Siemens
10.39 Smiths Medical
10.40 Servier
10.41 SOOIL Development
10.42 Takeda
10.43 TheraFuse
10.44 Teco Diagnostics
10.45 Transition Therapeutics
10.46 U.S. Diagnostics
10.47 VeraLight
10.48 Vivus
10.49 Ypsomed Holding

Appendix 1: Contact Information for Companies Profiled
Appendix 2: Prescribing Patterns for Anti-Hyperglycemic Drugs
Appendix 3: Detailed List of Insulins Available
Appendix 4: The History of Insulin
Appendix 5: Diabetes and Obesity Drugs in Development
Appendix 6: Pharmaceutical Sampling Practices

INDEX OF FIGURES

Figure 2.1: Worldwide Rates of Diabetes Cases, 2000-2025
Figure 2.2: Prevalence of Diabetes by Age in the U.S, 2007
Figure 2.3: New Adult Cases of Diabetes Diagnosed in the U.S., 2007
Figure 2.4: Distribution of Duration of Diabetes among Adults Aged 18 to 79 Years in the U.S., 2005
Figure 2.5: Number of Persons with Diagnosed Diabetes in the U.S., 1980-2007
Figure 2.6: Treatment with Insulin or Oral Medication among Adults Diagnosed with Diabetes, 2007
Figure 2.7: Rate of New Diabetes Cases among Children in the U.S., 2007
Figure 2.8: Expenditure Associated with Diabetes Complications in the U.S., 2007
Figure 2.9: Diabetes Death Rate by Race and Sex in the U.S., 1979-2006
Figure 3.1: Prevalence of Complications in Diabetics vs. People with Normal Blood Sugar Levels, 2007
Figure 3.2: Per Capita Costs for Diabetes-related Complications per Year, 2007
Figure 3.3: Total Spending on Healthcare in the U.S., 1960-2008
Figure 3.4: Percentage Breakdown of U.S. Healthcare Spending, 2008
Figure 3.5: Percentage of U.S. Population that Smokes, 1965-2005
Figure 3.6: Heart Disease Death Rate by Race and Sex in the U.S., 1979-2006
Figure 3.7: Hypertension Drugs Newly Prescribed or Continued in the U.S., 1994-2007
Figure 3.8: Annual Death Rate of U.S. Population from Strokes, 1950-2008
Figure 3.9: U.S. Male and Female Population Death Rates from Strokes, 2008
Figure 3.10: Annual Death Rate of U.S. Population from Heart Disease, 1950-2008
Figure 3.11: Percentage of U.S. Population that is Overweight, 1976-2004
Figure 4.1: Medical Research in the U.S. Outpaces the Rest of the World
Figure 4.2: Cost of Diabetes in the U.S., 2007
Figure 4.3: Top Therapeutic Classes Contributing to Drug Trend, 2007
Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2006
Figure 5.1: Comparison of the Effects of the Pioglitazone and Rosiglitazone on Lipids
Figure 5.2: U.S. Non-Insulin Anti-Diabetes Sales, 2006
Figure 5.3: Sales Forecast for the Global Diabetes Market, 1992-2012
Figure 6.1: Insulin Pump Market Share, 2007
Figure 6.2: Relative Risk of Diabetes Complications by Mean HbA1c
Figure 9.1: Relationship between Diabetes Therapy and the Proposed Timeline
Figure A3.1: Novo Nordisk¡¦s Rising Market Share in the U.S. Insulin Market, 1982-2008

INDEX OF TABLES

Table 1.1: Criteria for the Diagnosis of Diabetes
Table 2.1: Top Ten Countries in Number of Diabetics (20 to 79 Age Group) in the World, 2007 and 2025
Table 2.2: Annual Estimated Cost of Diabetes Care in the U.S., 2007
Table 2.3: Impact of Diabetes on Americans
Table 2.4: How Diabetes Dollars are Spent in the U.S., 2007
Table 3.1: Percentage of GDP Healthcare Spending by Country, 2008
Table 3.2: Life Expectancy Rate by Country, 2008
Table 3.3: Normal Glucose Values¡XFasting State
Table 3.4: Percentage of Adults Smokers by Country, 2008
Table 3.5: Worldwide Market for Cardiac Care Therapeutics, 2003-2010
Table 3.6: Death Rate from Cardiovascular Diseases by Country, 2008
Table 4.1: Leading Therapy Classes for R&D, 2008
Table 4.2: Pharmaceutical R&D Expenditures by World Region, 1990-2007
Table 4.3: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2007
Table 4.4: Global Pharmaceutical Sales, 2007
Table 4.5: World Pharmaceutical Sales Share by Region, 2007
Table 4.6: The World¡¦s Top-Selling Drugs (Audited Market), 2007
Table 4.7: Pharmaceutical Product Sales by Country Market, 2007
Table 4.8: Top Ten Global Pharmaceutical Companies by Global Sales, 2007
Table 4.9: Leading Therapy Classes by Global Pharmaceutical Sales (Audited Market), 2007
Table 4.10: Leading Ten Therapeutic Classes by U.S. Sales, 2003-2007
Table 4.11: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2006 and 2007
Table 4.12: Top Ten Brand Drugs by U.S. Retail, 2007
Table 4.13: Worldwide Anti-Diabetes Drug Market, 2006-2012
Table 4.14: Oral Anti-Diabetic Therapy Major World Markets, 2006
Table 4.15: The Leading Ten Anti-Diabetics by Sales, 2007
Table 4.16: Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes, 2008
Table 4.17: Summary of Glucose-Lowering Interventions as Monotherapy
Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
Table 5.2: Average Dose and Cost Comparison of Hypoglycemic Agents
Table 5.3: Relative Efficacy of Diabetes Drugs
Table 5.4: Thiazolidinediones Available for Type 2 Diabetes Mellitus
Table 5.5: Fixed Drug Combinations
Table 5.6: GLP-1 Pipeline: Selected Drugs in Development that Target GLP-1
Table 5.7: DPP-IV Inhibitor Pipeline
Table 6.1: Available Therapeutic Insulin Alternatives
Table 6.2: Worldwide Insulin Sales, 2005-2012
Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2007
Table 6.4: Worldwide Insulin Sales and Market Share by Company, 2007
Table 6.5: U.S. Insulin Sales and Market Share by Company, 2007
Table 6.6: U.S. Retail Insulin Sales, 2006-2009
Table 6.7: Comparison of Rapid-Acting Insulins
Table 6.8: Comparison of Long-Acting Insulins
Table 6.9: Pharmacokinetics of Available Insulins
Table 6.10: Status of Inhaled Insulin Products, 2009
Table 6.11: Key Drivers of the Type 2 Diabetes Insulin Market, 2012
Table 6.12: A Comparison of Existing Insulin Delivery Devices
Table 6.13: Lancet Characteristics
Table 6.14: Lancing Device Characteristics
Table 6.15: Insulin Pens
Table 6.16: Worldwide Demand for Insulin Injector Pens by Volume, 2006-2010
Table 6.17: Injection Aids
Table 6.18: Jet Injectors
Table 6.19: Leading Insulin Pump Manufacturers
Table 6.20: External Insulin Pumps
Table 6.21: Comparison of Current Insulin Pumps on the Market
Table 6.22: Control Averages by Treatment
Table 6.23: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
Table 6.24: Worldwide Diabetes Market, 2008
Table 6.25: Types of Insulin Pumps on the Market
Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
Table 7.2: Cells of the Pancreas
Table 7.3: Lipoprotein Risk Levels and Treatment Goals in Adult Patients with Diabetes
Table 7.4: Agents for Lowering Lipid Levels in Patients with Dyslipidemia
Table 7.5: Suggested Pharmacological Treatment Agents for Hypertension in Patients with Diabetes
Table 7.6: Selected Mid-2008 Press Releases on Emerging Anti-Diabetes Agents
Table 7.7: Diabetes Agents in the Pipeline
Table 7.8: Future Anti-Diabetic Drugs in Late-Stage Development
Table 8.1: Laboratory Assessment of Diabetic Vascular Disease
Table 8.2: Worldwide Market for Diabetes Self-Testing (Meters, Strips and Lancets), 2004-2012
Table 8.3: Market for Glucose Self-Testing in the U.S., 2004-2012
Table 8.4: U.S. Sales for OTC Blood Glucose Meters and Strips, 2007
Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2008
Table 9.2: Selected Licensing Deals in the Diabetes Arena, 2003-2008
Table 9.3: Top Therapeutic Categories in U.S. Development, 2008
Table 9.4: Pharmaceutical Companies by Number of Products in R&D Pipeline, 2007
Table 9.5: Pharmaceutical Companies by Number of Diabetes Products in Development
Table 9.6: Selected New Diabetes Drugs in Pipeline, 2007
Table 9.7: Comparison of New Molecular Entity Outcomes for FDA and EMEA (Jan 2006 to October 2008)
Table 9.8: Upcoming Milestones for Selected Diabetes Drugs
Table 9.9: Overview of Blockbuster Drugs Coming Off-Patent, 2008 to 2012
Table A1.1: Company Headquarters Contact Information
Table A3.1: Current Insulins
Table A4.1: Select Archived Press Release Excerpts
Table A5.1: The Diabetes/Obesity Pipeline by Developmental Stage, 2009

- Abbott Laboratories
- Amgen
- AstraZeneca
- Bayer
- BodyMedia
- Cybermedical
- Debiotech
- DexCom
- Echo Therapeutics
- Eksigent
- Elixir Pharmaceuticals
- Flamel Technologies
- GlaxoSmithKline
- GlucoLight
- Insulet
- Isis Pharmaceuticals, Inc.
- Johnson & Johnson
- KYORIN
- M-Biotech
- Medtronic
- Menarini
- Merck & Co.
- Merck KGaA
- MicroIslet
- Mitsubishi Tanabe Pharma Corporation
- Nipro Diabetes Systems
- Novartis
- Novo Nordisk
- Novocell
- ONO Pharmaceutical
- Orexigen Therapeutics
- Pfizer
- ReNeuron
- Roche Diagnostics
- SOOIL Development
- Sanofi-Aventis
- Servier
- Siemens
- Smiths Medical
- Takeda
- Teco Diagnostics
- TheraFuse
- Transition Therapeutics
- U.S. Diagnostics
- VeraLight
- Vivus
- Ypsomed Holding
- iSense Corporation

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos